Let’s kick off this week’s roundup with some good old computing
Much ado about APUs
Scalability.org has a number of posts on APUs (of which FPGAs are a subset). A couple of weeks ago, there was a post about some discussions the scalability folks had with VCs. More recently there was commentary on APU programming and a discussion on the APU market and possible success factors. As I have said before, I like the concept of accelerator cards, and the potential processing power they bring to the table. What makes me more circumspect are the various barriers to adoption, and the need (or realization of one) for APUs in the mainstream scientific computing market. I just feel that the way they are marketed is somewhat limiting. Vendors need to find applications that show a clear benefit and also ways to make code development a lot easier and scalable (the latter is an area where scalability.org is as good a resource as any)
The next 2.0
With all the 2.0′s around, I believe that some sort of compendium is required, so that the world can keep pace. Which is why a recent Bio-IT World headline entitled Revolution 2.0 made me chuckle a little bit. The article in question is about Gene Network Sciences, a biosimulation company with origins in Ithaca, NY. Regardless of the title, the article is an interesting read, and covers other players in the field, some of the different approaches, and the sheer challenges of being a company in the still young, albeit fascinating, field. I should send out a shout to the company that first attracted me to this field, Physiome Sciences (now part of Predix). Some of the original Physiome people now run the BioAnalytics Group
THe FDA under fire
When the Institute of Medicine rips the FDA, one has to to take the issue seriously, and the FDA is certainly taking the report seriously. I am sure there are some obvious things in the report, but in the long term everyone will benefit from patient, carefully thought out changes. I always worry about kneejerk, politically driven changes, which usually backfire badly.
The Tripoli Six
Normally I avoid politics like the plague, but Declan Butler’s article was the final straw. I just wanted to add my voice of support.
Things I noticed #7
Let’s kick off this week’s roundup with some good old computing
Much ado about APUs
Scalability.org has a number of posts on APUs (of which FPGAs are a subset). A couple of weeks ago, there was a post about some discussions the scalability folks had with VCs. More recently there was commentary on APU programming and a discussion on the APU market and possible success factors. As I have said before, I like the concept of accelerator cards, and the potential processing power they bring to the table. What makes me more circumspect are the various barriers to adoption, and the need (or realization of one) for APUs in the mainstream scientific computing market. I just feel that the way they are marketed is somewhat limiting. Vendors need to find applications that show a clear benefit and also ways to make code development a lot easier and scalable (the latter is an area where scalability.org is as good a resource as any)
The next 2.0
With all the 2.0′s around, I believe that some sort of compendium is required, so that the world can keep pace. Which is why a recent Bio-IT World headline entitled Revolution 2.0 made me chuckle a little bit. The article in question is about Gene Network Sciences, a biosimulation company with origins in Ithaca, NY. Regardless of the title, the article is an interesting read, and covers other players in the field, some of the different approaches, and the sheer challenges of being a company in the still young, albeit fascinating, field. I should send out a shout to the company that first attracted me to this field, Physiome Sciences (now part of Predix). Some of the original Physiome people now run the BioAnalytics Group
THe FDA under fire
When the Institute of Medicine rips the FDA, one has to to take the issue seriously, and the FDA is certainly taking the report seriously. I am sure there are some obvious things in the report, but in the long term everyone will benefit from patient, carefully thought out changes. I always worry about kneejerk, politically driven changes, which usually backfire badly.
The Tripoli Six
Normally I avoid politics like the plague, but Declan Butler’s article was the final straw. I just wanted to add my voice of support.
Technorati Tags: FPGA, Biosimulation, Tripoli Six, FDA, Drug Safety, Regulation, Scientific Computing, High Performance Computing
powered by performancing firefox